Serum GDF-15 Levels Accurately Differentiate Patients with Primary Mitochondrial Myopathy, Manifesting with Exercise Intolerance and Fatigue, from Patients with Chronic Fatigue Syndrome. — CFSMEATLAS
Serum GDF-15 Levels Accurately Differentiate Patients with Primary Mitochondrial Myopathy, Manifesting with Exercise Intolerance and Fatigue, from Patients with Chronic Fatigue Syndrome.
Bermejo-Guerrero, Laura, de Fuenmayor-Fernández de la Hoz, Carlos Pablo, Guerrero-Molina, María Paz et al. · Journal of clinical medicine · 2023 · DOI
Quick Summary
This study tested whether a blood marker called GDF-15 could help doctors tell the difference between ME/CFS and a rare condition called primary mitochondrial myopathy (PMM), which affects how cells produce energy. Both conditions cause fatigue and exercise intolerance that can look very similar, but PMM requires different treatment. The researchers found that GDF-15 levels were very good at distinguishing between these two conditions, which could help patients get the right diagnosis faster without needing extensive genetic testing or muscle biopsies.
Why It Matters
Many ME/CFS patients undergo extensive and sometimes invasive testing to rule out mitochondrial disease, which causes significant burden and cost. A simple, accurate blood test could reduce unnecessary investigations, accelerate diagnosis, and help identify the subset of fatigued patients who actually have treatable mitochondrial disorders. This distinction is clinically important because mitochondrial myopathy requires specific management approaches.
Observed Findings
GDF-15 differentiated PMM from CFS with an AUC of 0.95 (excellent discrimination).
GDF-15 differentiated PMM from other non-mitochondrial disorders with an AUC of 0.94.
The study included 34 total patients: 7 with PMM, 22 with CFS, and 5 with other non-mitochondrial fatigue disorders.
Both PMM and CFS presented with clinically similar symptoms of fatigue and exercise intolerance.
Inferred Conclusions
GDF-15 is a promising biomarker to select which patients with fatigue warrant further investigation for mitochondrial disease.
GDF-15 could reduce the need for extensive genetic testing and muscle biopsies in CFS diagnostic workup.
A simple serum GDF-15 test may help clinicians triage fatigue patients more efficiently in primary care or specialist settings.
Remaining Questions
What is the optimal GDF-15 cutoff value for clinical decision-making, and does it vary by age, sex, or disease severity?
Does GDF-15 predict treatment response or prognosis in either PMM or CFS?
Can GDF-15 distinguish PMM from other metabolic or genetic mitochondrial conditions not included in this study?
What This Study Does Not Prove
This study does not prove that GDF-15 is elevated in PMM due to mitochondrial dysfunction specifically, only that it correlates with PMM diagnosis. The small sample size limits confidence in the true sensitivity and specificity in broader populations. Additionally, the study does not establish whether GDF-15 could discriminate PMM from other genetic or metabolic conditions that weren't included in this cohort.